Skip to main content Skip to section navigation Skip to footer
  • Visit us on Facebook
  • Visit us on Twitter
  • Visit us on Linkedin
Kintara Therapeutics, Inc.
  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Academic Collaboration
    • Advisors
  • Pipeline
    • Overview
    • REM-001
  • Clinical Trials
  • News & Media
    • Press Releases
    • Publications and Abstracts
    • Presentations
    • Recent News
    • Events
  • Investors
    • Overview
    • Analyst Coverage
    • News & Events
    • Company Info
    • Stock Info
    • SEC Filings
    • Governance
  • Contact
  • Careers

Publications and Abstracts

News & Media

News & Media

  • Press Releases
  • Publications and Abstracts
  • Presentations
  • Recent News
  • Events

European Association of Neuro-Oncology (EANO 2023)

Phase 2 Study of VAL-083 and Radiotherapy in Newly Diagnosed MGMT-unmethylated GBM: Case Study Reports

September 23, 2023

American Association for Cancer Research Annual Meeting 2023

VAL-083 in Patients with Recurrent Glioblastoma Treated under Expanded Access Program

April 17, 2023

American Association for Cancer Research Annual Meeting 2023

RELA Fusion-Positive Ependymoma and Diffuse Midline Glioma treated with VAL-083 under Expanded Access: Case Reports

April 17, 2023

Society for Neuro-Oncology Annual Meeting 2022

Phase 2 Study of VAL-083 and Radiotherapy in Newly Diagnosed MGMT-unmethylated GBM

November 18, 2022

Society for Neuro-Oncology Annual Meeting 2022

Recurrent RELA Fusion-Positive Ependymoma Treated with VAL-083 under Expanded Access: A Case Report

November 18, 2022

Society for Neuro-Oncology Annual Meeting 2022

VAL-083 in Patients with Recurrent Glioblastoma Treated under Expanded Access Program

November 18, 2022

American Association for Cancer Research Annual Meeting

Dianhydrogalactitol (VAL-083) for the Treatment of Glioblastoma Multiforme (GBM): Impact of Glucose Transporters for Crossing the Blood Brain Barrier (BBB)

April 11, 2022

Society for Neuro-Oncology Annual Meeting 2021

Phase 2 clinical trial of dianhydrogalactitol (VAL-083) in patients with newly diagnosed MGMT-unmethylated GBM

November 18, 2021

Society for Neuro-Oncology Annual Meeting 2021

Phase 2 study of dianhydrogalactitol (VAL-083) in patients with MGMT unmethylated, bevacizumab naïve glioblastoma in the adjuvant or recurrent setting

November 18, 2021

American Association for Cancer Research Annual Meeting

Phase 2 study of dianhydrogalactitol (VAL-083) in patients with MGMT-unmethylated, bevacizumab-naïve glioblastoma in the adjuvant or recurrent setting

April 10, 2021
rss_feed RSS
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Next Pagearrow_forward
©2025 Kintara Therapeutics, Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap Legal Information Manage Cookie Preferences